View More Recent Stories

Feb 24, 2025 04:58AM Travere Therapeutics (TVTX) PT Raised to $35 at Citi
Feb 20, 2025 05:19PM Travere Therapeutics (TVTX) Tops Q4 EPS by 17c
Feb 12, 2025 07:10AM Travere Therapeutics (TVTX) PT Raised to $32 at Scotiabank
Feb 12, 2025 06:36AM Travere Therapeutics (TVTX) PT Raised to $45 at Canaccord Genuity
Jan 22, 2025 03:23PM Travere Therapeutics (TVTX) call put ratio 2.7 calls to 1 put with a focus on a spreader of March 20 and 30 calls
Nov 30, 2024 10:00PM JPMorgan is out with its 2025 outlook for biotech stocks
Nov 19, 2024 11:00AM JPM just added these stocks to its Analyst Focus List - giving one 148% upside
Nov 8, 2024 06:11AM Travere Therapeutics (TVTX) Prices 7.81M Share Offering at $16/sh
Nov 7, 2024 04:02PM Travere Therapeutics (TVTX) Announces Proposed Share Offering
Oct 31, 2024 04:21PM Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI
Oct 29, 2024 10:11AM TD Cowen Reiterates Buy Rating on Travere Therapeutics (TVTX)
Oct 21, 2024 06:42AM Wells Fargo Upgrades Travere Therapeutics (TVTX) to Overweight
Oct 20, 2024 10:00AM 4 biotech stocks to own to benefit from key Q4 catalysts
Oct 17, 2024 07:01AM Travere Therapeutics (TVTX) and CSL Vifor Announce Swissmedic Approval of FILSPARI
Oct 10, 2024 05:26AM Wells Fargo Reiterates Equal Weight Rating on Travere Therapeutics (TVTX)
Oct 9, 2024 09:07AM Travere Therapeutics (TVTX) PT Raised to $13 at Stifel
Sep 30, 2024 06:59AM Travere Therapeutics (TVTX) PT Lowered to $22 at Canaccord Genuity
Sep 30, 2024 06:13AM Travere Therapeutics (TVTX) PT Raised to $18 at Barclays
Sep 27, 2024 07:39AM TD Cowen Reiterates Buy Rating on Travere Therapeutics (TVTX)
Sep 27, 2024 07:23AM Travere Therapeutics (TVTX) PT Lowered to $19 at Citi
Sep 27, 2024 06:43AM Travere Therapeutics (TVTX) PT Lowered to $18 at H.C. Wainwright
Sep 27, 2024 05:59AM Travere Therapeutics (TVTX) PT Lowered to $18 at BofA Securities
Sep 26, 2024 04:49PM After-hours movers: Costco, Scholastic Corp, Travere Therapeutics
Sep 26, 2024 04:01PM Travere Therapeutics (TVTX) Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase
Sep 10, 2024 07:23AM Travere Therapeutics (TVTX) PT Raised to $23 at Canaccord Genuity
Sep 6, 2024 09:49AM Travere Therapeutics (TVTX) PT Raised to $23 at Citi, 'Full Approval as Expected and We Expect Positive Inflection in Sales Trajectory'
Sep 6, 2024 06:12AM Travere Therapeutics (TVTX) PT Raised to $23 at H.C. Wainwright
Sep 6, 2024 05:42AM Travere Therapeutics (TVTX) PT Raised to $19 at BofA Securities
Sep 5, 2024 04:54PM Travere Therapeutics (TVTX) Halted, News Pending
Aug 28, 2024 09:00AM Piper Sandler Reiterates Neutral Rating on Travere Therapeutics (TVTX)
Aug 2, 2024 07:30AM Travere Therapeutics (TVTX) PT Raised to $12 at Piper Sandler
Aug 1, 2024 05:37PM Travere Therapeutics (TVTX) Tops Q2 EPS by 14c
View More Recent Stories